Table 4.
Univariate Analysis of Candidate SNPs of CYP2D6, CYP2E1 Genes and Risk of Doxorubicin Chemotherapy Induced Severe Toxicity of Non- Hematological Reactionsin Breast Cancer Patients.
| Anemia | Neutropenia | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene Name | Genotype | Grade ≤1 | Grade >1 | OR (95% CI) | p value | Grade ≤1 | Grade >1 | OR (95% CI) | p value |
| SNP | (n=88) | (n=16) | (n=70) | (n=34) | |||||
| CYP2D6*3 | A/A | 53 | 10 | 1 (Reference) | 41 | 22 | 1 (Reference) | ||
| rs35742686 | A/- + -/- | 35 | 6 | 0.90 (0.30-2.72) | 0.864 | 29 | 12 | 0.77 (0.32-1.80) | 0.548 |
| CYP2D6*4 | G/G | 56 | 8 | 1 (Reference) | 43 | 21 | 1 (Reference) | ||
| rs3892097 | G/A+A/A | 32 | 8 | 1.75 (0.59-5.11) | 0.306 | 27 | 13 | 0.98 (0.42-2.28) | 0.973 |
| CYP2D6*10 | C/C | 56 | 7 | 1 (Reference) | 45 | 18 | 1 (Reference) | ||
| rs1065852 | C/T+T/T | 32 | 9 | 2.25 (0.76-6.61) | 0.14 | 25 | 16 | 1.60 (0.69-3.67) | 0.268 |
| CYP2D6*17 | C/C | 53 | 9 | 1 (Reference) | 47 | 15 | 1 (Reference) | ||
| rs28371706 | C/T+T/T | 35 | 7 | 1.17 (0.40-3.45) | 0.765 | 23 | 19 | 2.58 (1.11-6.00) | 0.026* |
| CYP2E1*5B | G/G | 86 | 16 | 1 (Reference) | 69 | 33 | 1 (Reference) | ||
| rs2031920 | G/C+C/C | 2 | 0 | 1.04 (0.04-22.85) | 0.976 | 1 | 1 | 2.09 (0.12-34.43) | 0.606 |
| CYP2E1*6 | T/T | 52 | 11 | 1 (Reference) | 41 | 22 | 1 (Reference) | ||
| rs6413432 | T/A+A/A | 36 | 5 | 0.65 (0.21-2.05) | 0.469 | 29 | 12 | 0.77 (0.32-1.80) | 0.548 |
| CYP2E1*7B | G/G | 81 | 16 | 1 (Reference) | 63 | 34 | 1 (Reference) | ||
| rs6413420 | G/T+T/T | 7 | 0 | 0.32 (0.01-6.05) | 0.454 | 7 | 0 | 0.12 (0.06-2.21) | 0.155 |
| Fatigue | Bodyache | ||||||||
| Grade ≤1 | Grade >1 | Grade ≤1 | Grade >1 | ||||||
| (n=67) | (n=37) | (n=89) | (n=15) | ||||||
| CYP2D6*3 | A/A | 43 | 20 | 1 (Reference) | 53 | 10 | 1 (Reference) | ||
| rs35742686 | A/- + -/- | 24 | 17 | 1.52 (0.67-3.44) | 0.312 | 36 | 5 | 0.73 (0.23-2.33) | 0.602 |
| CYP2D6*4 | G/G | 42 | 22 | 1 (Reference) | 57 | 7 | 1 (Reference) | ||
| rs3892097 | G/A+A/A | 25 | 15 | 1.14 (0.50-2.60) | 0.746 | 32 | 8 | 2.03 (0.67-6.13) | 0.206 |
| CYP2D6*10 | C/C | 44 | 19 | 1 (Reference) | 54 | 9 | 1 (Reference) | ||
| rs1065852 | C/T+T/T | 23 | 18 | 1.81 (0.79-4.10) | 0.154 | 35 | 6 | 1.02 (0.33-3.14) | 0.96 |
| CYP2D6*17 | C/C | 37 | 25 | 1 (Reference) | 54 | 8 | 1 (Reference) | ||
| rs28371706 | C/T+T/T | 30 | 12 | 0.59 (0.25-1.37) | 0.221 | 35 | 7 | 1.35 (0.44-4.05) | 0.592 |
| CYP2E1*5B | G/G | 65 | 37 | 1 (Reference) | 87 | 15 | 1 (Reference) | ||
| rs2031920 | G/C+C/C | 2 | 0 | 0.34 (0.01-7.47) | 0.509 | 2 | 0 | 1.12 (0.05-24.66) | 0.938 |
| CYP2E1*6 | T/T | 40 | 23 | 1 (Reference) | 55 | 8 | 1 (Reference) | ||
| rs6413432 | T/A+A/A | 27 | 14 | 0.90 (0.39-2.05) | 0.805) | 34 | 7 | 1.41 (0.47-4.25) | 0.536 |
| CYP2E1*7B | G/G | 62 | 35 | 1 (Reference) | 82 | 15 | 1 (Reference) | ||
| rs6413420 | G/T+T/T | 5 | 2 | 0.70 (0.13-3.84) | 0.689 | 7 | 0 | 0.35 (0.01-6.53) | 0.485 |
SNP, Single nucleotide polymorphism; OR, Odds ratio; CI, Confidence interval; * indicates significance p< 0.05; p value determined based on χ2.